A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients

• Published in: Clinical therapeutics 2010-04, Vol.32 (4), p.649-658
• Main Authors: Zheng, Ming-Hua, MD, Shi, Ke-Qing, MD, Dai, Zhi-Juan, MD, Ye, Chao, MD, Chen, Yong-Ping, MD
• Format: Article
• Language: English
• Subjects: Adult; Antigens; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Biological and medical sciences; China; Clinical trials; DNA, Viral - blood; entecavir; Female; Guanine - adverse effects; Guanine - analogs & derivatives; Guanine - therapeutic use; HBeAg; HBV; Hepatitis B; Hepatitis B - genetics; Hepatitis B - immunology; Hepatitis B e Antigens - blood; Hepatitis B, Chronic - drug therapy; Hepatology; Human viral diseases; Humans; Infections; Infectious diseases; Internal Medicine; Male; Medical Education; Medical sciences; Nucleosides - adverse effects; Nucleosides - therapeutic use; Pharmacology. Drug treatments; Pyrimidinones - adverse effects; Pyrimidinones - therapeutic use; seroconversion; telbivudine; Thymidine - analogs & derivatives; Viral diseases; Viral hepatitis
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2010.04.001

Abstract Background: Because drug-resistant strains of hepatitis B virus (HBV) have developed, and because serum HBV-DNA levels may rebound in patients who receive treatment with nucleoside/nucleotide analogues for up to 2 years, there remains a largely unmet clinical need for agents to induce potent virologic suppression in the initial stage of the disease course of HBV infection. Objective: The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV. Methods: In this parallel-group, open-label trial, adult Chinese patients with previously untreated HBeAg-positive HBV (HBV-DNA concentration: ≥6 log10 copies/mL; alanine aminotransferase [ALT] level: ≥2 times the upper limit of normal) were randomized to receive telbivudine 600 mg or entecavir 0.5 mg daily for 24 weeks. Blood samples were collected at the baseline and at 12 and 24 weeks after the treatment. The primary end point was the mean reduction from baseline in serum HBV-DNA concentration at week 24. Secondary end points included mean reduction from baseline in serum HBV-DNA concentration at week 12, the absence of serum HBV-DNA, absence of serum HBeAg, HBeAg seroconversion at week 24, the normalization of serum ALT at week 24, and occurrence of adverse events through week 24. Results: A total of 131 patients were enrolled in the study: 91 men and 40 women, with a mean (SD) age of 32.5 (8.9) years. All patients were ethnic Han Chinese. The baseline demographic characteristics and serum HBV-DNA concentrations in the 2 treatment groups were well matched. Sixty-five patients were randomized to receive telbivudine and 66 to receive entecavir. The mean reductions from baseline in serum HBV-DNA were 4.99 and 4.69 log10 copies/mL at week 12, respectively, and 6.00 and 5.80 log10 copies/mL at week 24 (both time points, P = NS between groups). At week 12, HBV-DNA was undetectable in 43.1% (28/65) of the telbivudine group and 34.8% (23/66) of the entecavir group ( P = NS); at week 24, it was undetectable in 67.7% (44/65) of the telbivudine group and 57.6% (38/66) of the entecavir group ( P = NS). At week 12, HBeAg absence and seroconversion rates were significantly greater in the telbivudine group than the entecavir group (absence: 20.0% [13/65] vs 3.0% [2/66], respectively [ P = 0.002]; seroconversion: 13.8% [9/65] vs 3.0% [2/66] [ P = 0.030]). However, at week 24, HBeAg absence and seroconversi